These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 31200831)
1. c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. Tsakonas G; Botling J; Micke P; Rivard C; LaFleur L; Mattsson J; Boyle T; Hirsch FR; Ekman S Lung Cancer; 2019 Jul; 133():69-74. PubMed ID: 31200831 [TBL] [Abstract][Full Text] [Related]
2. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Kerr KM; Thunnissen E; Dafni U; Finn SP; Bubendorf L; Soltermann A; Verbeken E; Biernat W; Warth A; Marchetti A; Speel EM; Pokharel S; Quinn AM; Monkhorst K; Navarro A; Madsen LB; Radonic T; Wilson J; De Luca G; Gray SG; Cheney R; Savic S; Martorell M; Muley T; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dziadziuszko R; Vansteenkiste J; Weder W; Polydoropoulou V; Geiger T; Kammler R; Peters S; Stahel R; Lung Cancer; 2019 May; 131():95-103. PubMed ID: 31027705 [TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma. Kim IH; Lee IH; Lee JE; Hong SH; Kim TJ; Lee KY; Kim YK; Kim SJ; Sung SW; Park JK; Yoo IR; Kim YS; Kim JO; Kang JH Ann Surg Oncol; 2017 Mar; 24(3):770-777. PubMed ID: 27696172 [TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer. Li A; Niu FY; Han JF; Lou NN; Yang JJ; Zhang XC; Zhou Q; Xie Z; Su J; Zhao N; Huang Y; Wu YL Lung Cancer; 2015 Dec; 90(3):375-80. PubMed ID: 26791795 [TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer. Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258 [TBL] [Abstract][Full Text] [Related]
6. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases. Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411 [TBL] [Abstract][Full Text] [Related]
7. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer. Zhang J; Chen N; Qi J; Zhou B; Qiu X J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635 [TBL] [Abstract][Full Text] [Related]
8. Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance. Millares L; Barreiro E; Cortes R; Martinez-Romero A; Balcells C; Cascante M; Enguita AB; Alvarez C; Rami-Porta R; Sánchez de Cos J; Seijo L; Monsó E; Lung Cancer; 2018 Aug; 122():124-130. PubMed ID: 30032820 [TBL] [Abstract][Full Text] [Related]
9. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). Casadevall D; Gimeno J; Clavé S; Taus Á; Pijuan L; Arumí M; Lorenzo M; Menéndez S; Cañadas I; Albanell J; Serrano S; Espinet B; Salido M; Arriola E Oncotarget; 2015 Jun; 6(18):16215-26. PubMed ID: 26041880 [TBL] [Abstract][Full Text] [Related]
11. Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non-Small-Cell Lung Cancer. Gao HF; Li AN; Yang JJ; Chen ZH; Xie Z; Zhang XC; Su J; Lou NN; Yan HH; Han JF; Wu YL Clin Lung Cancer; 2017 Jan; 18(1):85-91. PubMed ID: 27461774 [TBL] [Abstract][Full Text] [Related]
12. Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA. Graziano SL; Lacas B; Vollmer R; Kratzke R; Popper H; Filipits M; Seymour L; Shepherd FA; Rosell R; Veillard AS; Taron M; Pignon JP Lung Cancer; 2013 Oct; 82(1):149-55. PubMed ID: 23920379 [TBL] [Abstract][Full Text] [Related]
13. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival. He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781 [TBL] [Abstract][Full Text] [Related]
15. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870 [TBL] [Abstract][Full Text] [Related]
16. Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients. Li X; Zhang C; Sun Z; Yang F; Xiao R; Sui X; Jiang G; Zhong W; Wang J Lung Cancer; 2019 Jul; 133():75-82. PubMed ID: 31200832 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis. Foster CC; Rusthoven CG; Sher DJ; Feldman L; Pasquinelli M; Spiotto MT; Koshy M Lung Cancer; 2019 Apr; 130():162-168. PubMed ID: 30885339 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10. Grieve S; Ding K; Moore J; Finniss M; Ray A; Lees M; Hossain F; Murugesan A; Agar J; Acar C; Taylor J; Shepherd FA; Reiman T ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32220948 [TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy. Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]